- Home
- CLLS vs REPL Comparison
CLLS vs REPL Comparison
Compare CLLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | REPL |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 407.1M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CLLS | REPL |
|---|---|---|
| Price | $3.16 | $10.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $8.33 | $5.67 |
| AVG Volume (30 Days) | 28.7K | ★ 3.1M |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $1.50 |
| 52 Week High | $5.48 | $13.24 |
Technical Indicators
Market Signals| Indicator | CLLS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 62.42 |
| Support Level | $2.86 | $9.69 |
| Resistance Level | $3.40 | $12.50 |
| Average True Range (ATR) | 0.16 | 0.90 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 44.93 | 42.83 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.